Teva Pharmaceutical's quixotic efforts to develop a next-generation multiple sclerosis therapy hit another snag as safety issues forced the company to limit dosing in a pair of ongoing trials designed to support approval.
Earlier this year, U.S. regulators updated the label of Novartis' multiple sclerosis pill, Gilenya, to reflect cases of serious brain infections linked to the treatment. And now, its counterparts across the pond are following suit.
Scientists studying the way in which multiple sclerosis develops say they have identified a new mechanism of action behind the disease that may offer a new pathway for drug developers.
What's the best path forward for healthcare brands? It starts with making a difference and serving the people they're working to connect with, according to Digitas Health executive director Graham Mills--and that's something he says marketers in the multiple sclerosis space already do exceptionally well.
A UCLA researcher says that giving the pregnancy hormone estriol to multiple sclerosis patients along with their regular medications helped reduce the number of relapses the group suffered from. And now she's hunting for enough financial support to put her work to a pivotal clinical test.
A Phase III trial of MedDay's multiple sclerosis drug has missed its primary endpoint. The drug, which made headlines in April when it was shown to improve mobility, failed to outperform the placebo in terms of improving the vision of people with multiple sclerosis.
Teva did everything in its power to block generic copies of lead drug Copaxone from hitting the market. But now that one is here--Novartis' Glatopa--the Israeli drugmaker's giant is faring better than industry watchers expected.
Sanofi's Aubagio may be stepping out of the shadow of its rivals. For the third quarter, Aubagio brought in €225 million ($247 million), an amount easily dwarfed by Gilenya's $696 million and Tecfidera's $937 million. But that was a major leap for Aubagio--81%--compared with slowing growth for the other two meds.
Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.
Biogen, Sanofi and Novartis are all touting new data showing long-term benefits for their respective meds at this year's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting--and with tough new competition on the way, they may need it.